The Selection of Pregnancy for Patients After Tubal Ectopic Pregnancy Treatment
TSOPFPATEPT
1 other identifier
observational
400
1 country
1
Brief Summary
The incidence of re-ectopic pregnancy in patients with tubal ectopic pregnancy increases significantly, which may be related to the condition of the fallopian tubes, such as tubal inflammation, tubal obstruction and other high-risk factors that may lead to tubal ectopic pregnancy; it is also associated with the treatment of the previous tubal ectopic pregnancy. Compared with salpingectomy, the treatment of preserving the fallopian tubes increased the incidence of re-ectopic pregnancy while increasing the pregnancy rate of the patient. For tubal-preserving patients, the most common option currently used is to recommend that monitoring ovulation during each menstrual cycle if they choose to conceive naturally rather than IVF. If ovulation occures on the healthy side of the ovary, it may be considered to try to conceive; Otherwise, contraception is recommended. However, there are uncertainties about this option. Based on this, we intend to conduct a multicenter clinical trial to verify the effectiveness of the ovulation preparation regimen on the healthy side of ovary.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 10, 2022
CompletedFirst Posted
Study publicly available on registry
August 12, 2022
CompletedStudy Start
First participant enrolled
January 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedAugust 12, 2022
August 1, 2022
10 months
August 10, 2022
August 10, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Rate of tubal pregnancy within12 months in both groups of patients.
Tubal ectopic pregnancy refers to the implantation of embryo in the fallopian tubes.
2023.10
Secondary Outcomes (1)
Rates of pregnancy and miscarriage within 12 months in both groups of patients.
2023.10
Study Arms (2)
Ovulation occurs on the healthy side
In tubal-presering patient who received treatment of tubal ectopic pregnancy,only when ovulation occurs on the healthy side of ovary,it may be considered to try to conceive; otherwise, contraception is recommended.
Ovulation occurs on the either side
In tubal-presering patient who received treatment of tubal ectopic pregnancy,ovulation occurs on the either side of ovary,it may be considered to try to conceive.
Interventions
No intervention.
Eligibility Criteria
Patients with fertility needs who received tubal-preserving treatment during prior tubal ectopic pregnant in Shanghai First Maternity and Infant Hospital, Shanghai Zhoupu Hospital, Shanghai Seventh People's Hospital.
You may qualify if:
- After tubal pregnancy treatment (including expectant therapy, medication, salpingotomy), the blood hCG value returns to normal;
- The patient has fertility requirements;
- The age of the patient is between 18-41 years old;
- Regular menstruation;
- There is no abnormality in the husband's semen examination;
- No history of sex hormone drugs in the 3 months prior to the examination;
- No underlying diseases such as heart, liver, kidneys and brain;
- No history of tuberculosis;
- Normal blood routine examination (WBC≥ 4\*109/L, HB≥100g/L, PLT≥100\*109/L);
- Normal liver and kidney function tests;
- Normal thyroid function;
- The patient can withstand and receive follicle monitoring during pregnancy;
- Negative for pregnancy test before treatment.
You may not qualify if:
- Cervical pregnancy, cesarean scar pregnancy, cornual pregnancy, interstitial pregnancy;
- The age of the patient \< 18 years or \> 41 years;
- Irregular menstruation or abnormal results of sex hormone tests during follow-up;
- Abnormal results of the man's semen examination during the follow-up period;
- The patient has a tendency to bleed easily;
- History of myometriosis and endometriosis;
- Abnormal blood routine examination or liver and kidney function;
- History of cardiovascular diseases, including severe hypertension, severe arrhythmias, history of myocardial infarction;
- History of hepatitis B or C infection and patient has a detectable viral load;
- Patients with active tuberculosis;
- History of malignant tumors;
- Unable to regularly monitor the follicles during pregnancy;
- Unconditional long-term follow-up;
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Shanghai First Maternity and Infant Hospitallead
- Shanghai 7th People's Hospitalcollaborator
- Shanghai Zhoupu Hospitalcollaborator
- Shanghai Pudong Hospitalcollaborator
Study Sites (1)
Shanghai First Maternity and Infant Hospital
Shanghai, Shanghai Municipality, 200120, China
Related Publications (1)
Mol F, van Mello NM, Strandell A, Strandell K, Jurkovic D, Ross J, Barnhart KT, Yalcinkaya TM, Verhoeve HR, Graziosi GCM, Koks CAM, Klinte I, Hogstrom L, Janssen ICAH, Kragt H, Hoek A, Trimbos-Kemper TCM, Broekmans FJM, Willemsen WNP, Ankum WM, Mol BW, van Wely M, van der Veen F, Hajenius PJ; European Surgery in Ectopic Pregnancy (ESEP) study group. Salpingotomy versus salpingectomy in women with tubal pregnancy (ESEP study): an open-label, multicentre, randomised controlled trial. Lancet. 2014 Apr 26;383(9927):1483-1489. doi: 10.1016/S0140-6736(14)60123-9. Epub 2014 Feb 3.
PMID: 24499812RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 10, 2022
First Posted
August 12, 2022
Study Start
January 1, 2023
Primary Completion
October 30, 2023
Study Completion
December 31, 2023
Last Updated
August 12, 2022
Record last verified: 2022-08